Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) - Investment analysts at HC Wainwright decreased their Q1 2027 earnings per share (EPS) estimates for Alphatec in a report issued on Friday, November 13th. HC Wainwright analyst S. Lee now anticipates that the medical technology company will earn $0.03 per share for the quarter, down from their prior forecast of $0.08. HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Alphatec's current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Alphatec's Q2 2027 earnings at $0.07 EPS, Q3 2027 earnings at $0.07 EPS and Q4 2027 earnings at $0.15 EPS.
Several other research analysts have also recently issued reports on the stock. Needham & Company LLC reduced their target price on shares of Alphatec from $14.00 to $12.00 and set a "buy" rating for the company in a report on Friday, October 30th. TD Cowen decreased their target price on shares of Alphatec from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, October 30th. Weiss Ratings lowered shares of Alphatec from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday. JPMorgan Chase & Co. cut their price target on Alphatec from $16.00 to $15.00 and set an "overweight" rating on the stock in a research report on Friday, October 30th. Finally, BMO Capital Markets lowered Alphatec from an "outperform" rating to a "market perform" rating and set a $8.00 price objective for the company. in a research note on Friday, October 30th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.37.
View Our Latest Stock Analysis on Alphatec
Alphatec Stock Down 4.1%
ATEC stock opened at $6.78 on Tuesday. The firm's fifty day simple moving average is $9.70 and its 200-day simple moving average is $10.12. Alphatec has a 12 month low of $6.72 and a 12 month high of $23.29.
Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The business had revenue of $221.17 million for the quarter, compared to analysts' expectations of $225.16 million. During the same period in the prior year, the business posted $0.03 earnings per share. The business's quarterly revenue was up 12.6% compared to the same quarter last year.
Institutional Trading of Alphatec
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATEC. Kopp Family Office LLC raised its position in shares of Alphatec by 0.4% in the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company's stock worth $3,408,000 after acquiring an additional 1,303 shares during the period. Valeo Financial Advisors LLC boosted its stake in shares of Alphatec by 7.2% during the 2nd quarter. Valeo Financial Advisors LLC now owns 44,363 shares of the medical technology company's stock worth $384,000 after acquiring an additional 2,967 shares in the last quarter. Allworth Financial LP grew its position in shares of Alphatec by 82.6% during the 2nd quarter. Allworth Financial LP now owns 6,666 shares of the medical technology company's stock valued at $58,000 after acquiring an additional 3,015 shares during the period. Sterling Capital Management LLC grew its position in shares of Alphatec by 841.5% during the 3rd quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company's stock valued at $42,000 after acquiring an additional 3,669 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in shares of Alphatec by 1.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 318,319 shares of the medical technology company's stock valued at $3,463,000 after acquiring an additional 4,643 shares during the period. Institutional investors and hedge funds own 66.35% of the company's stock.
Insider Buying and Selling
In other news, CEO Patrick Miles bought 115,000 shares of the firm's stock in a transaction that occurred on Thursday, September 10th. The stock was purchased at an average cost of $8.81 per share, for a total transaction of $1,013,150.00. Following the purchase, the chief executive officer directly owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. This trade represents a 1.99% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David M. Demski purchased 60,000 shares of the stock in a transaction that occurred on Friday, October 30th. The shares were purchased at an average cost of $6.81 per share, for a total transaction of $408,600.00. Following the completion of the acquisition, the director directly owned 491,635 shares of the company's stock, valued at $3,348,034.35. This represents a 13.90% increase in their position. The SEC filing for this purchase provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.48% of the stock is owned by company insiders.
About Alphatec
(
Get Free Report)
Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company's product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alphatec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.
While Alphatec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.